HUTCHMED (China) Limited (HCM) on Wednesday said results from the Phase III SACHI trial evaluating savolitinib in combination with osimertinib were published in The Lancet.
The SACHI study, conducted in China, assessed the combination compared to platinum-based doublet chemotherapy, in patients with epidermal growth factor receptor (EGFR) mutation-positive, MET-amplified non-small cell lung cancer (NSCLC) whose disease had progressed following first-line EGFR tyrosine kinase inhibitor therapy.
The trial met its primary endpoint, with an objective response rate (ORR) of 58% in the savolitinib plus osimertinib arm, compared with 34% in the chemotherapy arm. The disease control rate (DCR) was 89% versus 67%, while median duration of response (DoR) was 8.4 months versus 3.2 months, respectively.
The savolitinib and osimertinib combination was approved in China in June 2025.
HUTCHMED shares rose more than 4% in after-market trading after closing up 0.13% at $14.95.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.